Moderna said it is curbing investments in late‑stage infectious disease vaccine trials following political backlash in the U.S., a move reported amid industry concerns about the policy environment for vaccine development. The company’s leadership told Bloomberg the decision reflects changing risk calculations as regulatory and public scrutiny intensify. The shift could narrow late‑stage mRNA vaccine portfolios and affect public‑private planning for future outbreak responses.